Wenjing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wenjing Wang has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Yingjie Xu
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 shared publications - Binyin Li
Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
1 shared publication - Fang Xie
Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China
1 shared publication - Hang Yu
Shanghai RNACure Biopharma Co, Ltd, Shanghai, China (Y. Zou, J. Lu, H. Yu)
1 shared publication - Jiahui Wang
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation Shanghai Jiao Tong University School of Medicine Shanghai P.R. China
1 shared publication - Jie Wang
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China
1 shared publication
Latest Publications
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e243423
Identifying Distinct Spatiotemporal Patterns of Juxtacortical Microstructure in Alzheimer Disease Using Diffusion MRI–derived Free Water Fraction
Juxtacortical free water fraction, determined at diffusion MRI, was higher in participants with Alzheimer disease compared with cognitively normal controls and associated with amyloid-β, tau, and neurodegeneration biomarkers, revealing two distinct spatiotemporal progression patterns with different impacts on neuroanatomic signatures and cognitive performance.
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (1) , e243423
Identifying Distinct Spatiotemporal Patterns of Juxtacortical Microstructure in Alzheimer Disease Using Diffusion MRI–derived Free Water Fraction
Juxtacortical free water fraction, determined at diffusion MRI, was higher in participants with Alzheimer disease compared with cognitively normal controls and associated with amyloid-β, tau, and neurodegeneration biomarkers, revealing two distinct spatiotemporal progression patterns with different impacts on neuroanatomic signatures and cognitive performance.
- 28 May 2025
- Published by American Diabetes Association in Diabetes
- Vol. 74 (8) , 1427-1440
Codelivery of NGFR100W and VEGFA mRNA Enhances Vascular and Neural Repair in Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathy (DPN) poses significant clinical challenges due to progressive nerve degeneration and vascular insufficiency. To address both neural and vascular complications simultaneously, we employed an mRNA-based protein replacement therapy. In this study, leveraging mRNA template design, structure-based screening identified NGFR100W as a variant dissociating neuroprotective and nociceptive functions, demonstrating enhanced neuritogenic activity without pain sensitization. Additionally, transcriptome analysis of NGF mutants versus wild type further reveals the potential mechanism by which NGFR100W uncouples neuroprotective and nociceptive pathways. We cotransfected chemically modified NGFR100W mRNA and vascular endothelial growth factor A (VEGFA) mRNA, and the conditioned media collected from this transfection promoted endothelial cell migration, tubulogenesis, and neurite outgrowth. In a diabetic mouse model, combination therapy with lipid nanoparticle codelivery of NGFR100W and VEGFA mRNA significantly improved blood flow in the plantar region and mitigated nerve function decline compared with monotherapy. Histological analysis showed increased microvessel formation and higher intraepidermal nerve fiber density in treated mice. Our findings highlight the therapeutic potential of NGFR100W and VEGFA mRNA coadministration for DPN, suggesting that protein supplementation via mRNA could offer a novel strategy for clinical intervention in some chronic medical conditions. Article Highlights: We aimed to develop a dual-targeted mRNA-based therapy to address both neural degeneration and vascular insufficiency in diabetic peripheral neuropathy. We identified NGFR100W as a mutation that enhances neuritogenic activity without pain sensitization and investigated its transcriptome to explore its ability to uncouple neuroprotective and nociceptive pathways. Combination therapy using lipid nanoparticles for codelivery of NGFR100W and VEGFA mRNA improved blood flow, increased microvessel formation, and preserved nerve function in a diabetic mouse model. This approach, which combines structure-based design and mRNA therapy, offers a novel strategy for decoupling protein functions and developing therapeutic molecules with specific functionalities.
- 28 May 2025
- Published by American Diabetes Association in Diabetes
- Vol. 74 (8) , 1427-1440
Codelivery of NGFR100W and VEGFA mRNA Enhances Vascular and Neural Repair in Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathy (DPN) poses significant clinical challenges due to progressive nerve degeneration and vascular insufficiency. To address both neural and vascular complications simultaneously, we employed an mRNA-based protein replacement therapy. In this study, leveraging mRNA template design, structure-based screening identified NGFR100W as a variant dissociating neuroprotective and nociceptive functions, demonstrating enhanced neuritogenic activity without pain sensitization. Additionally, transcriptome analysis of NGF mutants versus wild type further reveals the potential mechanism by which NGFR100W uncouples neuroprotective and nociceptive pathways. We cotransfected chemically modified NGFR100W mRNA and vascular endothelial growth factor A (VEGFA) mRNA, and the conditioned media collected from this transfection promoted endothelial cell migration, tubulogenesis, and neurite outgrowth. In a diabetic mouse model, combination therapy with lipid nanoparticle codelivery of NGFR100W and VEGFA mRNA significantly improved blood flow in the plantar region and mitigated nerve function decline compared with monotherapy. Histological analysis showed increased microvessel formation and higher intraepidermal nerve fiber density in treated mice. Our findings highlight the therapeutic potential of NGFR100W and VEGFA mRNA coadministration for DPN, suggesting that protein supplementation via mRNA could offer a novel strategy for clinical intervention in some chronic medical conditions. Article Highlights: We aimed to develop a dual-targeted mRNA-based therapy to address both neural degeneration and vascular insufficiency in diabetic peripheral neuropathy. We identified NGFR100W as a mutation that enhances neuritogenic activity without pain sensitization and investigated its transcriptome to explore its ability to uncouple neuroprotective and nociceptive pathways. Combination therapy using lipid nanoparticles for codelivery of NGFR100W and VEGFA mRNA improved blood flow, increased microvessel formation, and preserved nerve function in a diabetic mouse model. This approach, which combines structure-based design and mRNA therapy, offers a novel strategy for decoupling protein functions and developing therapeutic molecules with specific functionalities.
- 9 December 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (23) , e70244
mRNA ‐encoded fluorescent proteins enable superior organelle labeling for live cell imaging
Live cell labeling of various organelles is of great demand in the research field of cell biology. However, current approaches often lack an optimal balance between efficiency and versatility. We took advantage of chemical modified mRNA to express various organelle located fluorescent proteins. This approach facilitated highly efficient multi‐organelle labeling across diverse cell types, both in vitro and in vivo. The application of mRNA‐based organelle markers offers faster and more efficient transfection and expression compared to plasmids. When expressing fluorescent proteins in neuronal cells, it is faster and safer compared to viral vectors. Notably, this approach excels in rapidly labeling organelles, making it highly effective for dynamic live cell imaging applications. By leveraging this tool, we unveiled the unique behaviors of mitochondria and the endoplasmic reticulum during spike protein‐mediated cell fusion, a critical event in SARS‐CoV‐2 viral entry. Thus, our results demonstrate the potency of mRNA‐encoded fluorescent proteins as powerful tools for advancing biological research.
- 9 December 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (23) , e70244
mRNA ‐encoded fluorescent proteins enable superior organelle labeling for live cell imaging
Live cell labeling of various organelles is of great demand in the research field of cell biology. However, current approaches often lack an optimal balance between efficiency and versatility. We took advantage of chemical modified mRNA to express various organelle located fluorescent proteins. This approach facilitated highly efficient multi‐organelle labeling across diverse cell types, both in vitro and in vivo. The application of mRNA‐based organelle markers offers faster and more efficient transfection and expression compared to plasmids. When expressing fluorescent proteins in neuronal cells, it is faster and safer compared to viral vectors. Notably, this approach excels in rapidly labeling organelles, making it highly effective for dynamic live cell imaging applications. By leveraging this tool, we unveiled the unique behaviors of mitochondria and the endoplasmic reticulum during spike protein‐mediated cell fusion, a critical event in SARS‐CoV‐2 viral entry. Thus, our results demonstrate the potency of mRNA‐encoded fluorescent proteins as powerful tools for advancing biological research.